U.S., April 1 -- ClinicalTrials.gov registry received information related to the study (NCT07502521) titled 'Dexrazoxane to Protect Against Hemorrhagic STEMI' on March 26.
Brief Summary: This Phase Ila randomized trial evaluates whether the intravenous administration of Dexrazoxane can reduce permanent heart muscle damage in patients undergoing standard stent procedures (PCI) for a severe heart attack (STEMI).
Study Start Date: Aug. 30, 2025
Study Type: INTERVENTIONAL
Condition:
Acute Myocardial Infarction (AMI)
Intervention:
DRUG: Dexrazoxane
Intravenous infusion administered adjunctively to primary PCI
DRUG: Normal Saline (0.9% NaCl)
Visually identical placebo infusion administered adjunctively to primary PCI.
Recruitment Statu...